| |
Remark |
 G Protein-coupled receptors
|
|
|
Cytokine receptors
|
|
|
Nuclear receptors
|
|
|
Ion channels
|
|
|
Transporters
|
|
|
Enzymes
|
|
|
Protein kinases
|
|
|
 Cytokines
|
Class I cytokines
|
Class II cytokines
|
PDGF family
|
TNF family
|
TNF-alpha [HSA:7124] [KO:K03156]
|
Etanercept [ATC:L04AB01]
|
Infliximab [ATC:L04AB02]
|
 D02598 Infliximab (genetical recombination) (JAN); Infliximab (USAN/INN)
|
Monoclonal antibody
|
Adalimumab [ATC:L04AB04]
|
Certolizumab pegol [ATC:L04AB05]
|
Golimumab [ATC:L04AB06]
|
Lenalidomide [ATC:L04AX04]
|
Afelimomab
|
Lenercept
|
Nerelimomab
|
Onercept
|
Ozoralizumab
|
Pegsunercept
|
LTA [HSA:4049] [KO:K05468]
|
LTB [HSA:4050] [KO:K03157]
|
Lymphotoxin [HSA:4049 4050] [KO:K05468 K03157]
|
TNFSF4 (OX40L) [HSA:7292] [KO:K05469]
|
CD40L (CD154) [HSA:959] [KO:K03161]
|
RANKL [HSA:8600] [KO:K05473]
|
APRIL [HSA:8741] [KO:K05475]
|
BAFF [HSA:10673] [KO:K05476]
|
IL-1 family
|
IL-17 family
|
TGF-beta family
|
Chemokines
|
|
|
Others
|
Target-based Classification of Drugs